Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
- 15 March 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1255-1263
Abstract
The BTK inhibitor ibrutinib and the BCL‐2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2‐year fixed‐duration, oral‐based, chemotherapy‐free regimen in symptomatic, treatment‐naive WM patients. All patients had MYD88 mutations, 17 (38%) had CXCR4 mutations, and 4 (9%) had TP53 alterations. Following enrollment of 45 patients, treatment and enrollment were stopped due to the occurrence of ventricular arrhythmias in 4 (9%), which included two grade 5 events. The median treatment time was 10 cycles, each lasting 28 days. Follow‐up continued after protocol treatment was terminated. The very good partial response/complete response (VGPR/CR) rate was 42%, and it was lower in patients with CXCR4 (29% vs. 50%) or TP53 (25% vs. 44%) mutations. With a median follow‐up of 49 months, the median progression‐free survival (PFS) was 36 months (range 28–42). The median treatment‐free survival (TFS) and overall survival (OS) were not reached, and the 4‐year TFS and OS rates were 73% and 91%, respectively. The median PFS after end of therapy (PFS‐EOT) was 29 months. TP53 mutations were associated with inferior PFS, TFS, and PFS‐EOT, while CXCR4 mutations did not adversely impact these outcomes. Given the deep and durable responses seen in this study, concurrent BTK and BCL‐2 inhibition warrants further development in WM. TP53 mutations emerged as an adverse factor in WM in this combination study.Keywords
Funding Information
- AbbVie
- Pharmacyclics
This publication has 22 references indexed in Scilit:
- Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2026
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesNEJM Evidence, 2022
- Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaLeukemia, 2021
- TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaBritish Journal of Haematology, 2018
- Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundAmerican Journal of Hematology, 2018
- The BCL2 antagonist ABT‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild‐type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cellsBritish Journal of Haematology, 2015
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003